FireCyte Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Series A
- (Upcoming)
- Investors
-
4
FireCyte Therapeutics General Information
Description
Developer of novel treatment strategies intended to focus on the role of microglia and neuroinflammation in progressive neurodegenerative diseases of the eye. The company leverages novel protein constructs that engage both microglia and neurons, with a focus on the development of therapeutics that mitigate harmful neuroinflammatory disease processes and promote neuroprotection, enabling healthcare professionals to address unmet needs in glaucoma, age-related macular degeneration and other neurodegenerative diseases.
Contact Information
Website
www.firecyte.comCorporate Office
- 100 Cummings Center
- Suite 451-C
- Beverly, MA 01915
- United States
Corporate Office
- 100 Cummings Center
- Suite 451-C
- Beverly, MA 01915
- United States
FireCyte Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A) | Upcoming | Pre-Clinical Trials | ||||
| 2. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 1. Seed Round | 01-Feb-2022 | $12M | $12M | Completed | Pre-Clinical Trials |
FireCyte Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
FireCyte Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
FireCyte Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
FireCyte Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| Mass General Brigham Ventures | Venture Capital | Minority | ||
| Morningside Group | Venture Capital | Minority | ||
| InnoVentures Lab | Accelerator/Incubator |
FireCyte Therapeutics FAQs
-
When was FireCyte Therapeutics founded?
FireCyte Therapeutics was founded in 2021.
-
Where is FireCyte Therapeutics headquartered?
FireCyte Therapeutics is headquartered in Beverly, MA.
-
What is the size of FireCyte Therapeutics?
FireCyte Therapeutics has 6 total employees.
-
What industry is FireCyte Therapeutics in?
FireCyte Therapeutics’s primary industry is Drug Discovery.
-
Is FireCyte Therapeutics a private or public company?
FireCyte Therapeutics is a Private company.
-
What is FireCyte Therapeutics’s current revenue?
The current revenue for FireCyte Therapeutics is .
-
How much funding has FireCyte Therapeutics raised over time?
FireCyte Therapeutics has raised $12M.
-
Who are FireCyte Therapeutics’s investors?
AbbVie Ventures, Mass General Brigham Ventures, Morningside Group, and InnoVentures Lab have invested in FireCyte Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
